Terminated PHASE1 INTERVENTIONAL 2-arm NCT01159873

Single Ascending-Dose Study to Characterize the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-37251 in Healthy Postmenopausal Women

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending-Dose Study to Characterize the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-37251 in Healthy Postmenopausal Women

Sponsor: Cephalon

Conditions Bone Loss Osteoporosis

Interventions CEP-37251 Placebo

Updated 6 times since 2017 Last updated: May 9, 2014 Started: Jul 31, 2010 Primary completion: Oct 31, 2010 Completion: Oct 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study has been stopped by sponsor decision

Other terminated trials from Cephalon

See all terminations from Cephalon

A PHASE1 clinical study on Bone Loss and Osteoporosis, this trial is terminated or withdrawn. The trial is conducted by Cephalon and has accumulated 6 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2022 — Jul 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jan 2022 [monthly]

Terminated PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Terminated PHASE1

First recorded

Jul 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cephalon

Data source: Teva Branded Pharmaceutical Products R&D, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Adelaide, Australia